Engineering the Future of Oligonucleotide Manufacturing
Next-generation solutions that reimagine how technology moves the world forward. Continuous manufacturing start to finish.
Batch processing of Oligonucleotides has been in use for ~4 decades. Physical limitations minimize the scalability to 10-15 kg per batch and limits patient access.
The current capabilities are not able to accommodate new blockbuster medications for Alzheimer’s and obesity.
Continuous manufacturing of oligonucleotides reduces waste, increases yield, purity and efficiency all while massively reducing CAPEX/kg of DS produced.
Solving the scalability problem
Who We Are
We’re a collective of visionary scientists and engineers dedicated to disrupting the status quo and accelerating technological evolution in Oligonucleotide Manufacturing. Experts in organic, analytical and process chemistry, chemical and mechanical engineering and material sciences bring several decades of experience and a vast network to solve any problem.
By merging breakthrough research with real-world application, we pioneer solutions that make the future tangible today.